Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART).

doi:10.1371/journal.pone.0134158

Article

Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART).

PloS one - 1 Jan 2015

Dold Leona, Ahlenstiel Golo, Althausen Eva, Luda Carolin, Schwarze-Zander Carolynne, Boesecke Christoph, Wasmuth Jan-Christian, Rockstroh Jürgen Kurt, Spengler Ulrich

Abstract excerpt

BACKGROUND AND AIMS: HLA class I alleles, in particular HLA-B*57, constitute the most consistent host factor determining outcomes in untreated HCV- and HIV-infection. In this prospective cohort study, we analysed the impact of HLA class I alleles on all-cause mortality in patients with HIV-, HCV- and HIV/HCV- co-infection receiving HAART. METHODS: In 2003 HLA-A and B alleles were determined and patients were...

Topics

Adolescent
Adult
Aged
Aged, 80 and over
Alleles
Anti-HIV Agents
Antiretroviral Therapy, Highly Active
CD4 Lymphocyte Count
Coinfection
Disease Progression

Follow-Up Studies

Gene Frequency

Genes, MHC Class I

Genes, MHC Class II

Genotype

HIV Infections

HLA-A Antigens

HLA-B Antigens

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.